Skip to main content
. 2021 Apr 19;2021(4):CD011535. doi: 10.1002/14651858.CD011535.pub4

16.

16

Distributions of age (on the left, mean age in years in the y axis) and PASI score at baseline (on the right, mean PASI in the y axis) ratio of participants across comparisons (x axis)

ACI: acitretin; ADA: adalimumab; APRE: apremilast; BIME: bimekizumab; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; IXE: ixekizumab; GUSEL: guselkumab; MIRI: mirikizumab; MTX: methotrexate; PBO: placebo; RISAN: risankizumab; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; TYK2: Oral Tyrosine kinase 2 inhibitor; USK: ustekinumab